In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...

The Kentucky Attorney General’s Office on Thursday announced more than $19.8 million was awarded to 75 Kentucky organizations ...

Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

Wave Life Sciences Ltd.’s WVE share price has dipped by 10.08%, which has investors questioning if this is right time to buy.

Longevity drug developer Loyal and pain therapy manufacturer Elanco Animal Health are working with the organization to ...

The firm will seek accelerated approval for WVE-N531 in DMD amenable to exon 53 skipping based on FDA feedback and Phase II data.

The integration of AI and cloud technologies is transforming pharmaceutical manufacturing regulations, focusing on safety, efficiency, and global harmonization.

Wave Life Sciences (NASDAQ:WVE) announced Wednesday its plans to file a New Drug Application (NDA) with the U.S. FDA in 2026 to seek the regulator’s accelerated approval for WVE-N531, an experimental ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...